ישראל - עברית - Ministry of Health

bionicare israel ltd. - רופא - סטימולטור להפחתת כאבים בברך

ישראל - עברית - Ministry of Health

bioavenir ltd - alendronic acid as sodium 70 mg - tablets - alendronic acid - alendronate bioavenir is indicated for the treatment of osteoporosis in postmenopausal women to prevent fractures, including those of the hip and spine (vertebral compression fractures) .

ישראל - עברית - Ministry of Health

bioavenir ltd, israel - pantoprazole as sodium - אבקה להכנת תמיסה לזריקה - pantoprazole as sodium 40 mg/vial - pantoprazole - pantoprazole - for the treatment of duodenal ulcer, gastric ulcer , moderate and severe forms of reflux oesophagitis. zollinger ellison syndrome.

ישראל - עברית - Ministry of Health

bioavenir ltd - lactulose 66.7 g / 100 ml - solution (oral) - lactulose - chronic constipation. acute and chronic hepatic encephalopathy.

ישראל - עברית - Ministry of Health

bioavenir ltd - lactulose 66.7 g / 100 ml - solution (oral) - lactulose - chronic constipation. acute and chronic hepatic encephalopathy.

ישראל - עברית - Ministry of Health

bioavenir ltd, israel - furosemide - תמיסה לאינפוזיה - furosemide 250 mg / 25 ml - furosemide - furosemide - for use only in treating patients with extremely reduced glomerular filtration.in acute renal insufficiency . in chronic renal insufficiency .oliguria in acute or chronic renal failure.

ישראל - עברית - Ministry of Health

bioavenir ltd - losartan as potassium 50 mg - tablets - losartan - hypertension: losartan is indicated for the treatment of heart failure ( nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to tiasar is not recommended. renal protection in type - 2 diabetic patients with proteinuria: losartan is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease ( need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrphy. losartan is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrphy. the benefit of tiasar on the primary deposite end poin

ישראל - עברית - Ministry of Health

bioavenir ltd - losartan as potassium 100 mg - tablets - losartan - hypertension: losartan is indicated for the treatment of heart failure ( nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to tiasar is not recommended. renal protection in type - 2 diabetic patients with proteinuria: losartan is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease ( need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrphy. losartan is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrphy. the benefit of tiasar on the primary deposite end poin

ישראל - עברית - Ministry of Health

bioavenir ltd - pravastatin sodium 40 mg - tablets - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute coronary events. myocardial infa

ישראל - עברית - Ministry of Health

bioavenir ltd, israel - aciclovir - אבקה להכנת תמיסה לאינפוזיה - aciclovir 250 mg - aciclovir - aciclovir - for the treatment of herpes simplex infections and severe intial genital herpes in the non immunocompromised. for the prophylaxis of herpes simplex infections in immune-compromised patients. in the treatment of varicella zoster infections. for herpes simplex encephalitis. for the treatment of herpes simplex infection in the neonate and infant up to 3 months of age.